Cardiovascular Disease clinical trials

Explore recruiting cardiovascular disease clinical trials.

Recruiting cardiovascular disease studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cardiovascular Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Double-blind, Randomized,Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)

Spain, Hungary, Portugal, Greece, Germany, Italy +11 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

The cardiovascular safety and efficacy of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with established cardiovascular disease

France, Ireland, Netherlands, Poland, Denmark, Bulgaria +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)

France, Denmark, Germany, Spain, Italy, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

COLchicine and non-enteric coated aspirin in the Cardiovascular Outcomes Trial of patients with Type 2 Diabetes (COLCOT-T2D)

Finland, Portugal, Greece, Denmark, Italy, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established cardiovascular disease

Hungary, Czechia, Sweden, Italy, Netherlands, Germany +14 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Belgium, Hungary, Czechia, Austria, Germany, France +11 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Cardiovascular Disease trials by city

Cardiovascular Disease clinical trials

Recruiting cardiovascular disease studies right now

A Neurofeedback Interface in Poststroke Neuromodulation Using TMS-fNIRS

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

Effect of eHealth Cardiac Rehabilitation Incorporating Mindfulness for Patients With Coronary Heart Disease

Impact of Intraoperative Oxygenation Practices on Patient Outcomes

Inspiratory Muscle Strength Training for Lowering Blood Pressure and Improving Endothelial Function in Postmenopausal Women: Comparison With "Standard of Care" Aerobic Exercise

Implementation of IVS3 for Upper Limb Motor Recovery

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

Validation of the Masimo Irregular Heartbeat Detection Algorithm in Participants Without Cardiovascular Disease

Isometric Handgrip Training Frequency and Blood Pressure in People With Hypertension

Clinical Study of Endocardial Myocardial Biopsy

Investigating the Impact of Nudging Cardiologists to Prescribe Guideline-directed Medical Therapy in Heart Failure Patients

CorMatrix Cor TRICUSPID ECM Valve Replacement - Pivotal Study

Also recruiting in Europe

A Double-blind, Randomized,Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)

The cardiovascular safety and efficacy of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with established cardiovascular disease

COLchicine and non-enteric coated aspirin in the Cardiovascular Outcomes Trial of patients with Type 2 Diabetes (COLCOT-T2D)

A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established cardiovascular disease

Cardiovascular Disease trials by city

Other conditions